Literature DB >> 23519525

Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy.

Shunsuke Ishii1, Takayuki Inomata, Yuki Ikeda, Takeru Nabeta, Miwa Iwamoto, Ichiro Watanabe, Takashi Naruke, Hisahito Shinagawa, Toshimi Koitabashi, Mototsugu Nishii, Ichiro Takeuchi, Tohru Izumi.   

Abstract

Although an increased heart rate (HR) is a strong predictor of poor prognosis in cases of chronic heart failure (HF), the clinical value of HR as a predictor in acute decompensated HF (ADHF) is unclear. Seventy-eight patients with nonischemic dilated cardiomyopathy (NIDCM) with sinus rhythm who were first hospitalized for ADHF from 2002 to 2010 were retrospectively investigated after exclusion of patients with tachycardia-induced cardiomyopathy. The patients were divided into two groups stratified by HR on admission with a median value of 113 beats/min (Group H with HR ≥ 113 beats/min; Group L with HR < 113 beats/min). Despite similar backgrounds, including pharmacotherapy for HF, HR changes responding to titration of β-blocker (BB) therapy and myocardial interstitial fibrosis, left ventricular (LV) ejection fractions improved more significantly 1 year later in Group H than in Group L (57 % ± 11 % vs. 46 % ± 12 %, P < 0.001). Cardiac event-free survival rates were also significantly improved in Group H (P = 0.038). Multiple regression analysis revealed that only the peak HR on admission was an independent predictor of LV reverse remodeling (LVRR) 1 year later (β = 0.396, P = 0.005). High HR on first admission for ADHF is a strong predictor of LVRR, with a better prognosis in the event of NIDCM in response to optimal pharmacotherapy, independent of pre-existing myocardial damage and subsequent HR reduction by BB therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519525     DOI: 10.1007/s00380-013-0335-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  33 in total

1.  Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy.

Authors:  K Kawai; H Takaoka; K Hata; Y Yokota; M Yokoyama
Journal:  Am J Cardiol       Date:  1999-09-15       Impact factor: 2.778

2.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  S A Hunt; D W Baker; M H Chin; M P Cinquegrani; A M Feldman; G S Francis; T G Ganiats; S Goldstein; G Gregoratos; M L Jessup; R J Noble; M Packer; M A Silver; L W Stevenson; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; A K Jacobs; L F Hiratzka; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

3.  Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-.

Authors:  Tatsuo Aoki; Yoshihiro Fukumoto; Koichiro Sugimura; Minako Oikawa; Kimio Satoh; Makoto Nakano; Masaharu Nakayama; Hiroaki Shimokawa
Journal:  Circ J       Date:  2011-08-06       Impact factor: 2.993

4.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.

Authors:  Gregg C Fonarow; Kirkwood F Adams; William T Abraham; Clyde W Yancy; W John Boscardin
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

5.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

6.  Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint.

Authors:  T Yamada; M Fukunami; M Ohmori; K Iwakura; K Kumagai; N Kondoh; T Minamino; E Tsujimura; T Nagareda; K Kotoh
Journal:  J Am Coll Cardiol       Date:  1993-03-01       Impact factor: 24.094

7.  Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.

Authors:  Masatsugu Hori; Shigetake Sasayama; Akira Kitabatake; Teruhiko Toyo-oka; Shunnosuke Handa; Mitsuhiro Yokoyama; Masunori Matsuzaki; Akira Takeshita; Hideki Origasa; Kennichi Matsui; Saichi Hosoda
Journal:  Am Heart J       Date:  2004-02       Impact factor: 4.749

8.  Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure.

Authors:  Akira Matsumori
Journal:  Eur J Heart Fail       Date:  2003-10       Impact factor: 15.534

9.  Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study.

Authors:  M S Lauer; P M Okin; M G Larson; J C Evans; D Levy
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

10.  Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.

Authors:  Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez
Journal:  Circulation       Date:  2004-02-23       Impact factor: 29.690

View more
  16 in total

1.  Differences in ward-to-cath lab systolic blood pressure predicts long-term adverse outcomes after drug-eluting stent implantation.

Authors:  Ae-Young Her; Soe Hee Ann; Jun Ho Lee; Jong Min Kim; Yong Hoon Kim; Scot Garg; Gillian Balbir Singh; Eun-Seok Shin
Journal:  Heart Vessels       Date:  2014-07-26       Impact factor: 2.037

2.  Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.

Authors:  Toru Adachi; Akira Sato; Masako Baba; Daigo Hiraya; Tomoaki Hasegawa; Kenji Kuroki; Tomoya Hoshi; Kazutaka Aonuma
Journal:  Heart Vessels       Date:  2013-06-26       Impact factor: 2.037

3.  Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy.

Authors:  Yuki Ikeda; Takayuki Inomata; Yuichiro Iida; Miwa Iwamoto-Ishida; Takeru Nabeta; Shunsuke Ishii; Takanori Sato; Tomoyoshi Yanagisawa; Tomohiro Mizutani; Takashi Naruke; Toshimi Koitabashi; Ichiro Takeuchi; Mototsugu Nishii; Junya Ako
Journal:  Heart Vessels       Date:  2015-02-17       Impact factor: 2.037

4.  The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.

Authors:  Yasuki Nakada; Hiroyuki Takahama; Hideaki Kanzaki; Yasuo Sugano; Takuya Hasegawa; Takahiro Ohara; Makoto Amaki; Akira Funada; Akemi Yoshida; Satoshi Yasuda; Hisao Ogawa; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2015-05-12       Impact factor: 2.037

5.  Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure.

Authors:  Miho Fukui; Akiko Goda; Kazuo Komamura; Ayumi Nakabo; Mitsuru Masaki; Chikako Yoshida; Shinichi Hirotani; Masaaki Lee-Kawabata; Takeshi Tsujino; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2014-10-29       Impact factor: 2.037

6.  Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome.

Authors:  Shinpei Kadowaki; Tetsuro Shishido; Yuki Honda; Taro Narumi; Yoichiro Otaki; Daisuke Kinoshita; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Takuya Miyamoto; Tetsu Watanabe; Isao Kubota
Journal:  Heart Vessels       Date:  2015-01-24       Impact factor: 2.037

7.  The protective effect of heat shock protein 70 (Hsp70) in atrial fibrillation in various cardiomyopathy conditions.

Authors:  Too Jae Min; Won-Min Jo; Seung Yong Shin; Hong Euy Lim
Journal:  Heart Vessels       Date:  2014-06-03       Impact factor: 2.037

8.  Prognostic value of diastolic wall strain in patients with chronic heart failure with reduced ejection fraction.

Authors:  Yuko Soyama; Toshiaki Mano; Akiko Goda; Masataka Sugahara; Kumiko Masai; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-04-26       Impact factor: 2.037

9.  Diagnostic value of electrocardiographic P-wave characteristics in atrial fibrillation recurrence and tachycardia-induced cardiomyopathy after catheter ablation.

Authors:  Atsushi Doi; Masahiko Takagi; Hisashi Katayama; Tomotaka Yoshiyama; Yusuke Hayashi; Hiroaki Tatsumi; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2018-04-30       Impact factor: 2.037

10.  Effect of Ginkgo biloba extract on experimental cardiac remodeling.

Authors:  Wei Li; Zhenhua Luo; Xingde Liu; Lingyun Fu; Yini Xu; Lirong Wu; Xianchun Shen
Journal:  BMC Complement Altern Med       Date:  2015-08-13       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.